Latest news and insights on the pharmaceutical industry | Indian Pharma Post | Page 82

Results For "NAL"

6966 News Found

Bavarian Nordic bags $22.5M Canadian vaccine order
News | February 23, 2026

Bavarian Nordic bags $22.5M Canadian vaccine order

The order will cover the manufacturing of bulk vaccine in 2026


Siegfried delivers strong 2025 performance, bolsters US expansion
News | February 23, 2026

Siegfried delivers strong 2025 performance, bolsters US expansion

Net sales reached CHF 1,327.8 million, up 2.6% year-on-year in Swiss francs, or 4.3% at constant exchange rates


Morepen Labs lands record Rs. 825 crore global CDMO contract
News | February 23, 2026

Morepen Labs lands record Rs. 825 crore global CDMO contract

This multi-year CDMO agreement involves significant, ongoing manufacturing for a global pharmaceutical major


BMS reports positive Phase 2 data for Luspatercept in alpha-thalassemia
Clinical Trials | February 23, 2026

BMS reports positive Phase 2 data for Luspatercept in alpha-thalassemia

Both non-transfusion-dependent and transfusion dependent cohorts met their respective primary and secondary endpoints


Merck restructures Human Health division for future growth
News | February 23, 2026

Merck restructures Human Health division for future growth

Merck is currently conducting approximately 80 Phase 3 studies, and the company expects more than 20 new growth drivers over next several years, almost all with blockbuster potential


Maverick Simulation Solutions unveils ‘SIDDH’, India’s next-gen critical care patient simulator
Healthcare | February 22, 2026

Maverick Simulation Solutions unveils ‘SIDDH’, India’s next-gen critical care patient simulator

Our vision is to position India not just as a consumer of advanced simulation technologies but as a creator and exporter of them


Lilly’s Retevmo shows breakthrough results in early-stage lung cancer trial
Clinical Trials | February 22, 2026

Lilly’s Retevmo shows breakthrough results in early-stage lung cancer trial

The drug’s safety profile in LIBRETTO-432 aligned with previous selpercatinib studies, showing no unexpected concerns


Lonza scales bioconjugate innovation through enhanced synthesis offering
News | February 21, 2026

Lonza scales bioconjugate innovation through enhanced synthesis offering

Expansion at the Oss (NL) site adds capacity and R&D capabilities, supporting the development and manufacturing of ADCs and other novel bioconjugates from First-in-Human to commercialization